Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JTX 8064 + Pimivalimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JTX 8064 | JTX-8064|JTX8064 | LILRB2 Antibody 11 | JTX 8064 is an antagonist monoclonal antibody targeting LILRB2, which potentially induces macrophage polarization against tumor cells (PMID: 36780212). | |
Pimivalimab | JTX4014|JTX 4014|JTX-4014 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Pimivalimab (JTX-4014) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in restoration of anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04669899 | Phase I | JTX 8064 JTX 8064 + Pimivalimab JTX 8064 + Pembrolizumab | Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | Completed | USA | 0 |